1. Home
  2. NTRA vs BCE Comparison

NTRA vs BCE Comparison

Compare NTRA & BCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • BCE
  • Stock Information
  • Founded
  • NTRA 2003
  • BCE 1880
  • Country
  • NTRA United States
  • BCE Canada
  • Employees
  • NTRA N/A
  • BCE N/A
  • Industry
  • NTRA Medical Specialities
  • BCE
  • Sector
  • NTRA Health Care
  • BCE
  • Exchange
  • NTRA Nasdaq
  • BCE Nasdaq
  • Market Cap
  • NTRA 27.0B
  • BCE 20.2B
  • IPO Year
  • NTRA 2015
  • BCE N/A
  • Fundamental
  • Price
  • NTRA $199.57
  • BCE $23.14
  • Analyst Decision
  • NTRA Strong Buy
  • BCE Hold
  • Analyst Count
  • NTRA 18
  • BCE 3
  • Target Price
  • NTRA $206.17
  • BCE $33.50
  • AVG Volume (30 Days)
  • NTRA 1.3M
  • BCE 3.6M
  • Earning Date
  • NTRA 11-06-2025
  • BCE 11-06-2025
  • Dividend Yield
  • NTRA N/A
  • BCE 5.45%
  • EPS Growth
  • NTRA N/A
  • BCE 7324.86
  • EPS
  • NTRA N/A
  • BCE 4.80
  • Revenue
  • NTRA $2,116,676,000.00
  • BCE $17,579,277,614.00
  • Revenue This Year
  • NTRA $25.70
  • BCE $2.01
  • Revenue Next Year
  • NTRA $15.42
  • BCE $3.06
  • P/E Ratio
  • NTRA N/A
  • BCE $4.84
  • Revenue Growth
  • NTRA 38.17
  • BCE 0.11
  • 52 Week Low
  • NTRA $125.38
  • BCE $20.28
  • 52 Week High
  • NTRA $203.23
  • BCE $28.64
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 69.72
  • BCE 46.91
  • Support Level
  • NTRA $193.29
  • BCE $22.18
  • Resistance Level
  • NTRA $203.23
  • BCE $23.80
  • Average True Range (ATR)
  • NTRA 7.37
  • BCE 0.43
  • MACD
  • NTRA 0.25
  • BCE -0.06
  • Stochastic Oscillator
  • NTRA 80.29
  • BCE 43.81

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About BCE BCE Inc.

BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to movie channels including HBO, Showtime, and Starz.

Share on Social Networks: